Actively Recruiting
Study to Understand Characteristics, Treatment, and Access to New Therapies for Diffuse Large B-Cell Lymphoma Patients in the Middle East and Africa
Led by AstraZeneca · Updated on 2026-06-18
500
Participants Needed
21
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Diffuse large B-cell lymphoma DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma, with rapid tumor growth and symptoms varying by tumor location. The disease is classified using advanced methods like immunohistochemistry and molecular testing to guide prognosis and personalized treatment. Despite standard immunochemotherapy curing 60-70% of patients, many experience treatment failure or relapse, and options after second-line therapies remain limited. This observational study examines treatment patterns, demographic, and clinical characteristics of DLBCL patients in the Middle East and Africa. It includes two patient groups those newly diagnosed and eligible for treatment, and those with relapsed or refractory DLBCL who have failed previous therapies. The study aims to explore access to novel therapies and understand real-world treatment approaches in these regions. Participants will be observed over 22 months, during which researchers will document treatment regimens, patient risk profiles, and access to new treatments. Data collection includes patient demographics, disease characteristics, and treatment outcomes. The study does not involve experimental treatments but gathers detailed information to inform future care strategies for DLBCL patients.
CONDITIONS
Brief Title
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 18 years or older at diagnosis.
- Confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) according to investigator's decision or histopathological diagnosis.
- For Cohort 1: Patients eligible to start treatment for DLBCL as per investigator's decision.
- For Cohort 2: Patients with relapsed or refractory DLBCL who have failed at least one prior therapy.
- Willingness to sign informed consent and understand study procedures.
You will not qualify if you...
- Patients not eligible for treatment for any reason according to investigator's judgment.
- Presence of other active malignancies besides DLBCL.
- Current participation in any other clinical trial.
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here